Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
89 hedge funds and large institutions have $636M invested in Alder Biopharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 49 increasing their positions, 12 reducing their positions, and 8 closing their positions.
308% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 12
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
66% more capital invested
Capital invested by funds: $384M → $636M (+$252M)
19% more funds holding
Funds holding: 75 → 89 (+14)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$36.2M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$30.9M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$26.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$24.5M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$34.4M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$18.3M |
| 3 |
PC
PointState Capital
New York
|
-$5.09M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$2.43M |
| 5 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$2.41M |
ALDR Hedge Fund Activity: Q1 2015 in Review
89 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q1 2015, worth a combined $636M — up 66% from $384M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ALDR positions and 8 closed out — a net gain of 14 holders — while 49 added to existing stakes and 12 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $36.2M. The largest seller was Jennison Associates, exiting entirely with an estimated $34.4M sold.
- 89 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q1 2015, up from 75 in Q4 2014.
- Funds reported $636M of Alder Biopharmaceuticals stock for Q1 2015, up 66% quarter-over-quarter.
- 22 funds opened new Alder Biopharmaceuticals positions in Q1 2015 and 8 closed out, a net change of +14 holders.
- The largest Alder Biopharmaceuticals buyer in Q1 2015 was AllianceBernstein, an estimated $36.2M added.
- The largest Alder Biopharmaceuticals seller in Q1 2015 was Jennison Associates, an estimated $34.4M sold.
Based on aggregated 13F filings for Q1 2015.